Streetbeat News

NAMS

NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com

Industry

Biotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Open

20.74

Mkt cap

2.3B

Volume

1.1M

High

21.31

P/E Ratio

-8.20

52-wk high

27.29

Low

20.07

Div yield

N/A

52-wk low

15.19

NewAmsterdam Pharma's obicetrapib, a CETP inhibitor, shows promise in Phase 3 trials for lowering LDL-C, with plans for European approval in 2025. Its oral administration and lack of side effects could give it an edge over injectable competitors.

Portfolio Pulse from

March 01, 2025 | 4:45 am

NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures, obicetrapib's clean safety profile and efficacy position it well in the cardiovascular market. The PREVAIL trial is crucial for proving obicetrapib's ability to reduce major cardiovascular events, a key to regulatory approval and market adoption.

Portfolio Pulse from

February 28, 2025 | 4:00 pm

NewAmsterdam Pharma has released its full-year 2024 financial results and provided a corporate update. The company expects an EMA submission in the second half of 2025 through its partner Menarini. Additional data from its BROADWAY, BROOKLYN, and TANDEM studies will be presented throughout 2025.

Portfolio Pulse from

February 26, 2025 | 1:15 pm

NewAmsterdam Pharma (Nasdaq: NAMS) will participate in upcoming investor conferences in March. The company focuses on developing non-statin medicines for cardiovascular disease patients with high LDL-C levels.

Portfolio Pulse from

February 25, 2025 | 1:15 pm

NewAmsterdam Pharma has successfully closed an upsized $479 million public offering of ordinary shares and pre-funded warrants, including the full exercise of the underwriters' option to purchase additional shares. This move is aimed at supporting the company's development of non-statin medicines for cardiovascular disease.

Portfolio Pulse from

December 13, 2024 | 10:30 pm

NewAmsterdam Pharma's drug obicetrapib showed positive results in a phase 3 study, reducing LDL-C in patients with ASCVD and HeFH. This success paves the way for a potential FDA application in 2025, with further data releases and publications as future catalysts.

Portfolio Pulse from

December 11, 2024 | 6:45 pm

NewAmsterdam Pharma has announced a $300 million public offering of ordinary shares and pre-funded warrants. The offering is aimed at raising funds for the company's development of non-statin medicines for cardiovascular disease. The offering's completion is subject to market conditions.

Portfolio Pulse from

December 10, 2024 | 9:45 pm

NewAmsterdam Pharma announced positive results from its Phase 3 BROADWAY trial for Obicetrapib, showing significant LDL-C reduction in patients with cardiovascular disease or familial hypercholesterolemia.

Portfolio Pulse from

December 10, 2024 | 12:15 pm

NewAmsterdam Pharma's stock plummeted despite positive results from a cholesterol study showing a 50% reduction in LDL. The market reaction suggests other factors may be influencing investor sentiment.

Portfolio Pulse from

November 20, 2024 | 3:30 pm

NewAmsterdam Pharma (NASDAQ:NAMS) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month price target range of $31.00 to $37.00, with an average of $33.75, slightly up from the previous $33.00. The company shows strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.